Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Sirtuins: novel targets for metabolic disease.
Elliott PJ, Jirousek M. Elliott PJ, et al. Among authors: jirousek m. Curr Opin Investig Drugs. 2008 Apr;9(4):371-8. Curr Opin Investig Drugs. 2008. PMID: 18393104 Review.
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
Vu CB, Bemis JE, Disch JS, Ng PY, Nunes JJ, Milne JC, Carney DP, Lynch AV, Smith JJ, Lavu S, Lambert PD, Gagne DJ, Jirousek MR, Schenk S, Olefsky JM, Perni RB. Vu CB, et al. Among authors: jirousek mr. J Med Chem. 2009 Mar 12;52(5):1275-83. doi: 10.1021/jm8012954. J Med Chem. 2009. PMID: 19199480
Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo.
Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, Galonek HL, Israelian K, Song J, Razvadauskaite G, Lynch AV, Carney DP, Johnson RJ, Lavu S, Iffland A, Elliott PJ, Lambert PD, Elliston KO, Jirousek MR, Milne JC, Boss O. Smith JJ, et al. Among authors: jirousek mr. BMC Syst Biol. 2009 Mar 10;3:31. doi: 10.1186/1752-0509-3-31. BMC Syst Biol. 2009. PMID: 19284563 Free PMC article.
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Milne JC, et al. Among authors: jirousek mr. Nature. 2007 Nov 29;450(7170):712-6. doi: 10.1038/nature06261. Nature. 2007. PMID: 18046409 Free PMC article.
Protein kinase C inhibitors as novel anticancer drugs.
Goekjian PG, Jirousek MR. Goekjian PG, et al. Among authors: jirousek mr. Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40. doi: 10.1517/13543784.10.12.2117. Expert Opin Investig Drugs. 2001. PMID: 11772309 Review.
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M. Donovan JM, et al. Among authors: jirousek m. J Clin Pharmacol. 2017 May;57(5):627-639. doi: 10.1002/jcph.842. Epub 2017 Jan 11. J Clin Pharmacol. 2017. PMID: 28074489 Free PMC article. Clinical Trial.
51 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page